Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype.

The nonrandomized phase II study by Ding et al. explored the combination of azacitidine and chidamide with or without GemOx chemotherapy in relapsed/refractory peripheral T cell lymphoma and demonstrated that the dual epigenetic therapy is safe and efficacious, particularly in the angioimmunoblastic T cell lymphoma subset. Further investigation into adding chemotherapy is warranted, building on the promising results seen in this trial.